Minapharm Pharmaceuticals results, Fiscal year 2021
Net profit, assets, equity and cash flow for Fiscal year 2021, against the same period a year earlier, from the published financial statements.
Net profit466 millionEGP · +55.1% vs the same period a year earlier
Total assets4.11 billionEGP · +17.9% vs the same period a year earlier
Shareholders' equity1.94 billionEGP · +22.0% vs the same period a year earlier
Operating cash flow206 millionEGP · −52.9% vs the same period a year earlier
In short
- Minapharm Pharmaceuticals's net profit for Fiscal year 2021 was about 466 million EGP, up +55.1% from 301 million EGP in Fiscal year 2020.
- Total assets at the end of Fiscal year 2021 were about 4.11 billion EGP, and shareholders' equity about 1.94 billion EGP.
- Operating cash flow for Fiscal year 2021 was positive at 206 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2020Change
Net profit466 million301 million+55.1%
Gross profit1.26 billion985 million+28.3%
Total assets4.11 billion3.48 billion+17.9%
Total liabilities2.16 billion1.89 billion+14.4%
Shareholders' equity1.94 billion1.59 billion+22.0%
Total liabilities and equity4.11 billion3.48 billion+17.9%
Operating cash flow206 million437 million−52.9%
Investing cash flow-389 million-148 million−163.6%
Financing cash flow156 million-26.73 million+682.1%
Net change in cash-27.59 million263 million−110.5%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Minapharm Pharmaceuticals's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy